These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

811 related articles for article (PubMed ID: 26912618)

  • 1. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
    Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
    J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
    Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.
    Binka M; Ooms M; Steward M; Simon V
    J Virol; 2012 Jan; 86(1):49-59. PubMed ID: 22013041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity.
    Dang Y; Wang X; York IA; Zheng YH
    J Virol; 2010 Sep; 84(17):8561-70. PubMed ID: 20592083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.
    Han Y; Wang X; Dang Y; Zheng YH
    PLoS Pathog; 2008 Jul; 4(7):e1000095. PubMed ID: 18604271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif.
    Russell RA; Smith J; Barr R; Bhattacharyya D; Pathak VK
    J Virol; 2009 Feb; 83(4):1992-2003. PubMed ID: 19036809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APOBEC3 degradation is the primary function of HIV-1 Vif determining virion infectivity in the myeloid cell line THP-1.
    Ikeda T; Shimizu R; Nasser H; Carpenter MA; Cheng AZ; Brown WL; Sauter D; Harris RS
    mBio; 2023 Aug; 14(4):e0078223. PubMed ID: 37555667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
    Russell RA; Pathak VK
    J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.
    Chaipan C; Smith JL; Hu WS; Pathak VK
    J Virol; 2013 Jan; 87(1):444-53. PubMed ID: 23097438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
    He Z; Zhang W; Chen G; Xu R; Yu XF
    J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function.
    Albin JS; Haché G; Hultquist JF; Brown WL; Harris RS
    J Virol; 2010 Oct; 84(19):10209-19. PubMed ID: 20686027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Status of APOBEC3G/F in cells and progeny virions modulated by Vif determines HIV-1 infectivity.
    Yamashita T; Nomaguchi M; Miyake A; Uchiyama T; Adachi A
    Microbes Infect; 2010 Feb; 12(2):166-71. PubMed ID: 19944180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of 81LGxGxxIxW89 and 171EDRW174 domains from human immunodeficiency virus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity.
    Dang Y; Davis RW; York IA; Zheng YH
    J Virol; 2010 Jun; 84(11):5741-50. PubMed ID: 20335268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a novel WxSLVK motif in the N terminus of human immunodeficiency virus and simian immunodeficiency virus Vif that is critical for APOBEC3G and APOBEC3F neutralization.
    Dang Y; Wang X; Zhou T; York IA; Zheng YH
    J Virol; 2009 Sep; 83(17):8544-52. PubMed ID: 19535447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase.
    Liu B; Sarkis PT; Luo K; Yu Y; Yu XF
    J Virol; 2005 Aug; 79(15):9579-87. PubMed ID: 16014920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.
    Tian C; Yu X; Zhang W; Wang T; Xu R; Yu XF
    J Virol; 2006 Mar; 80(6):3112-5. PubMed ID: 16501124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dispersed sites of HIV Vif-dependent polyubiquitination in the DNA deaminase APOBEC3F.
    Albin JS; Anderson JS; Johnson JR; Harjes E; Matsuo H; Krogan NJ; Harris RS
    J Mol Biol; 2013 Apr; 425(7):1172-82. PubMed ID: 23318957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV restriction by APOBEC3 in humanized mice.
    Krisko JF; Martinez-Torres F; Foster JL; Garcia JV
    PLoS Pathog; 2013 Mar; 9(3):e1003242. PubMed ID: 23555255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.
    Bennett RP; Stewart RA; Hogan PA; Ptak RG; Mankowski MK; Hartman TL; Buckheit RW; Snyder BA; Salter JD; Morales GA; Smith HC
    Antiviral Res; 2016 Dec; 136():51-59. PubMed ID: 27825797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication.
    Peng J; Ao Z; Matthews C; Wang X; Ramdahin S; Chen X; Li J; Chen L; He J; Ball B; Fowke K; Plummer F; Embree J; Yao X
    J Mol Biol; 2013 Aug; 425(16):2840-52. PubMed ID: 23707381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.